Protalix should move to NASDAQ. Would show up on NASDAQ low list. Trades on little followed NYSE MKT.
Showing up on NASDAQ new lows list and NASDAQ biggest decliners list increases visibility. Protalix would probably show up in top 5 on NASDAQ decliners list today, since it is down over 10%.
Protalix should really move to NASDAQ where most biotechs trade to increase visibility. Moving to NASDAQ would also change to NASDAQ market makers. NYSE MKT is little followed, relatively small with about 290 stocks, and filled with mining, oil and gas stocks.